Contrasting Lunai Bioworks (LNAI) and Its Peers

Lunai Bioworks (NASDAQ:LNAI) is one of 451 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its rivals? We will compare Lunai Bioworks to related businesses based on the strength of its analyst recommendations, profitability, valuation, earnings, dividends, risk and institutional ownership.

Risk and Volatility

Lunai Bioworks has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Lunai Bioworks’ rivals have a beta of 10.26, indicating that their average stock price is 926% more volatile than the S&P 500.

Valuation & Earnings

This table compares Lunai Bioworks and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lunai Bioworks	N/A	-$178.01 million	-0.11
Lunai Bioworks Competitors	$440.86 million	-$69.10 million	-9.31

Lunai Bioworks’ rivals have higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and target prices for Lunai Bioworks and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1	0	0	0	1.00
Lunai Bioworks Competitors	4793	9961	16002	371	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 120.29%. Given Lunai Bioworks’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Lunai Bioworks has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Lunai Bioworks and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-222.12%	-152.88%
Lunai Bioworks Competitors	-2,625.49%	-359.63%	-43.39%

Summary

Lunai Bioworks rivals beat Lunai Bioworks on 9 of the 13 factors compared.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.